Dr. Sharon Castellino is the director of the Leukemia/Lymphoma (LL) program for the Aflac Cancer and Blood Disorders Center and also serves as the co-leader of the LL biorepository and vice-chair of the Aflac Precision Medicine Program protocol. 

Dr. Castellino’s overarching research is related to outcomes and late effects in Pediatric Leukemia and Lymphoma patients and survivors, with a focus on Hodgkin Lymphoma (HL).

She is the study chair for two Children’s Oncology Group (COG) trials for advanced stage HL. She also has leadership within the COG guidelines task force on survivorship care, with expertise in understanding hepatic late effects in childhood cancer.

Her investigator initiated research has been in retrospective data analyses of large datasets, with a focus on examining disparities in outcomes. In addition, Dr. Castellino has examined biomarkers of cardiovascular injury and has interests in cardio-oncology.

Nick DeGroote, MPH, Research epidemiologist

Current Project: Use of IVIG in pediatric B-ALL; Real world use of data in novel agents

Email: nicholas.degroote@choa.org


Himalee Sabnis, MD, Assistant Professor, Pediatric Hematology/Oncology

Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors

Email: himalee.sabnis@choa.org


Tamara Miller, MD, MSCE, Assistant Professor, Pediatric Hematology/Oncology

Current Project: Current Outcomes in pediatric ALL patients

View Research Profile 


Xu Ji, PhD, Health Services Researcher

View Research Profile


Holly Edington, MD, Fellow, Pediatric Hematology/Oncology

Education: University of North Carolina, Medical School, University of Toledo College of Medicine and Life Sciences, Residency, Eastern Virginia Medical School/Children’s Hospital of the King’s Daughters, Fellowship, Hematology/Oncology, Emory University/Children’s Healthcare of Atlanta

Current Project: Immunoglobulin administration and hypogammaglobulinemia during pediatric acute leukemia therapy

Fun Fact: I am a Big Ten college football fan.

Email: holly.edington@choa.org


Rebecca Lewis, MPH

Education: Undergraduate, University of Virginia, Charlottesville VA, Masters, Rollins School of Public Health, Emory University

Current Project: Late effects in pediatric patients who received tyrosine kinase inhibitors; validating cardiac care in childhood cancer survivors

Karen Effinger, MD, MSc, Assistant Professor, Pediatrics, Emory University, Aflac Cancer and Blood Disorders Center

Lane Miller, MD, MSc, Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center 

Justine Kahn, MD, MSc, Assistant Professor, Columbia University

Emily Silverman, Medical student, NYU Class of 2024

West ZE, *Castellino SM, Monroe C, Thomas AS, McCracken C, Miller TP. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 2020 Dec1:1-14 PMID 33258395(*co-first authors)

Castellino SM, Parsons SK, Kelly KM. Closing the survivorship gap in children and adolescents with Hodgkin Lymphoma. British J Haematol, 2019 Dec; 187(5): 573-58. PMID:31566730

Kahn J, Kelly KM, Pei, Q, Bush R, Friedman DL, Keller FG, Bhatia A, Henderson TO, Schwartz CL, Castellino, SM. Survival by race and ethnicity in children and adolescents with Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol, 2019 Nov 10;37(32):3009-3017. PMID:31539308

Blum KA, Keller FG, Castellino S, Phan A, Flowers CR. Incidence and outcomes of lymphoid malignancies in adolescent and young adult (AYA) patients in the United States. Br J Haematol. 2018 Nov; 183(3):385-399 PMID: 30095154

Keller FK, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton A, Bush R, Constine LS, Schwartz CL. Results of the AHOD0431 Trial of Response Adapted Therapy and a Salvage Strategy for Limited-Stage Classical Hodgkin Lymphoma: A Report from the Children’s Oncology Group. Cancer 2018 Aug; 124(15):3210-3219. PMID:29738613

Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. Br J Haematol. 2018 Jul; 182(2):212-221. PMID:29707774

Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A. Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in its Late Adolescence. J Pediatr Hematol Oncol. 2015 Apr;37(3):161-9. PMID: 25757020

Geiger AM, Castellino SM, Tooze JA, Altschuler A, Month S, Mertens AC, Nekhlyudov N, Greene SM. Potential role of community-based healthcare system data in research on survivors of adolescent and young adult cancer. J Adolesc Young Adult Oncol 2013 Jun 2(2):53-58. PMID 23781401

Geiger AM, Castellino SM. Delineating the Age Ranges Used to Define Adolescents and Young Adults. J Clin Oncol. 2011 Jun 1;29(16):e492-3. PMID: 21482981

Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and Mortality in Long-Term Survivors of Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study. Blood. 2011 Feb 10;117 (6):1806-16.PMID: 21037086

Metzger M, Castellino SM, Hudson MM, Rai SN, Kaste SC, Krasin MJ, Kun LE, Pui C, Howard SC. Effect of Race on the Outcome of Pediatric Patients with Hodgkin Lymphoma. J Clin Oncol 2008; 26(8):1282-8. PMID:18323551

Castellino SM, Casillas J, Hudson M, Mertens A, Whitton J, Brooks S, Zeltzer L, Ablin A, Castleberry R, Hobbie W, Kaste S, Robison L, Oeffinger K. Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization and health related behaviors from the childhood cancer survivor study (CCSS). J Clin Oncol 2005; 23:6499-507. PMID:16170159

Private Foundation Funding:

CURE Childhood Cancer - 7/1/2017-6/30/2022 

Aflac Precision Medicine: An investigation to create a systematic institutional approach to seek novel molecular abnormalities and potential therapy targets for all high risk cancer patients from diagnosis onward

Role: Co-I; Protocol Vice-Chair

PI: Graham


National Institutes of Health/Contracts:


Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)

Role: Co-PI

PI: Ji



Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors 

Role: Co-I

PI: Landier/Klosky



Mertens: SIP 20-004. Effect of Survivorship Care Plans on Cancer Mortality

Role: Co-I

PI: Kegler


COG-U10CA98543 - 12/1/2014-Present

AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Role: Study Chair

PI: Adamson


COG-U10CA98543 - 6/1/2019-5/31/2023

SWOG S1826: A Phase III Randomized Study of Nivolumab or Brentuximab Vedotin plus AVD in Patients (Age >/=12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma 

Role: Pediatric Study Chair (Overall Study Chair, Alex Herrera)

PI: Adamson


SurvivorLink - 10/1/2018-9/30/2023

Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers

Role: Advisory Board

Co-PI: Mertens/Escoffery 


K07CA211956-01A1 - 09/21/2017-08/31/2022

The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children’s hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.

Role: Mentor Team

PI: Tamara Miller

Bristol-Myers Squibb - 1/2016-10/1/2019 

1LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in children and adolescents

Role: Mentor/CoPI

Honoree, Researcher Appreciation Day, Emory School of Medicine, Atlanta, GA, Sept. 2020